Browse by Audience
Skip to content
Papers of the Week
Safety profile of lasmiditan in patients with migraine in an Asian population.
Authors
Abstract
MONONOFU, a multicenter, randomized, double-blind, placebo-controlled phase 2 study of Japanese patients with migraine, was pivotal for lasmiditan approval in Japan. However, treatment-emergent adverse events (TEAEs) were more common than in global studies. A detailed safety profile would assist patient management.